{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-006977","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2022-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.787066+00:00","generated_at":"2026-06-27T16:11:13.602158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte preliminary Q4 rev >$10M (+17% YoY); FY rev >$33.7M (+28%); adds 4 SPLs in 2021","bullets":["Q4 2021 preliminary revenue >$10.0M (up from $8.5M in Q4 2020); core business revenue grew at least 37%.","Full year 2021 revenue >$33.7M (up from $26.2M in 2020); program-related revenue $2.5M (vs $3.3M in 2020).","Installed base grew to >500 instruments (from >400); 15 SPLs covering >95 programs, over 15% in clinic.","Precommercial milestone potential from SPLs exceeds $1.25B (up from >$950M in 2020).","New SPLs: Nkarta, Myeloid Therapeutics, Celularity, Sana Biotechnology; ExPERT VLx instrument launched."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-006977","json":"https://secwatch.observer/filing/0001104659-22-006977.json","markdown":"https://secwatch.observer/filing/0001104659-22-006977.md","text":"https://secwatch.observer/filing/0001104659-22-006977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000110465922006977/0001104659-22-006977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000110465922006977/tm224229d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T16:11:13.602158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}